Quimby Investments

Variational AI is a preclinical therapeutics company that leverages advanced machine learning techniques to efficiently generate novel compounds optimized for various properties, thereby addressing common challenges in drug development. The company focuses on creating selective kinase inhibitors for solid tumors while also exploring additional target classes. By collaborating with leading biopharmaceutical partners, Variational AI aims to streamline the drug discovery process, enabling these partners to conduct multi-property molecular optimization. This approach significantly reduces the time needed to identify drug-like molecules with a higher likelihood of success in clinical trials. In addition to its collaborations, Variational AI is also developing its own internal pipeline of therapeutic candidates.

Arbutus Medical Inc., founded in 2014 and headquartered in Vancouver, Canada, specializes in the development and manufacturing of surgical power tools aimed at enhancing surgical efficiency and accessibility. The company offers a range of products, including its flagship orthopedic power tool system, which features innovative solutions such as the HEX and PRO drill kits, as well as sterile-packed orthopedic procedure kits. These tools are designed to meet the needs of various healthcare settings, including trauma centers, veterinary hospitals, military deployments, and hospitals in over 30 low- and middle-income countries. Arbutus Medical focuses on "frugal innovation," aiming to reduce healthcare costs and improve access to orthopedic surgery for millions of patients by 2030.

LightIntegra Technology Inc. is a medical diagnostics company based in Vancouver, Canada, founded in 2009. It specializes in in-vitro diagnostic tests aimed at improving platelet transfusion outcomes. Its primary product, ThromboLUX, provides both qualitative and quantitative analysis of microparticle content in platelet samples, which is essential for determining the suitability of platelet units for therapeutic or prophylactic use. The ThromboLUX test kit is complemented by a control kit and ThromboSight software, which assists healthcare professionals in analyzing test results. The company's innovation stems from research conducted in collaboration with Canadian Blood Services, led by Dr. Elisabeth Maurer, who utilized advancements in dynamic light scattering and laser technology to develop a rapid and effective diagnostic solution for assessing platelet quality and function.